Nurix Therapeutics (Nurix Therapeutics) Gross Margin % : 0.00% (As of Feb. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nurix Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Nurix Therapeutics's Gross Profit for the three months ended in Feb. 2024 was $16.59 Mil. Nurix Therapeutics's Revenue for the three months ended in Feb. 2024 was $16.59 Mil. Therefore, Nurix Therapeutics's Gross Margin % for the quarter that ended in Feb. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for Nurix Therapeutics's Gross Margin % or its related term are showing as below:

NRIX's Gross Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: 59.43
* Ranked among companies with meaningful Gross Margin % only.

Nurix Therapeutics had a gross margin of N/A% for the quarter that ended in Feb. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Nurix Therapeutics was 0.00% per year.

Nurix Therapeutics Gross Margin % Historical Data

The historical data trend for Nurix Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nurix Therapeutics Gross Margin % Chart

Nurix Therapeutics Annual Data

Trend

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Gross Margin %

Get a 7-Day Free Trial

Nurix Therapeutics Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Gross Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Nurix Therapeutics's Gross Margin %

For the Biotechnology subindustry, Nurix Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nurix Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Nurix Therapeutics's Gross Margin % falls into.

Nurix Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Nurix Therapeutics's Gross Margin for the fiscal year that ended in Nov. 2023 is calculated as

Gross Margin % (A: Nov. 2023 )	=	Gross Profit (A: Nov. 2023 )	/	Revenue (A: Nov. 2023 )
	=	77	/	76.987
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(76.987 - 0)	/	76.987
	=	N/A %

Nurix Therapeutics's Gross Margin for the quarter that ended in Feb. 2024 is calculated as

Gross Margin % (Q: Feb. 2024 )	=	Gross Profit (Q: Feb. 2024 )	/	Revenue (Q: Feb. 2024 )
	=	16.6	/	16.585
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(16.585 - 0)	/	16.585
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Nurix Therapeutics (NAS:NRIX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Nurix Therapeutics had a gross margin of N/A% for the quarter that ended in Feb. 2024 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Nurix Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Nurix Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nurix Therapeutics (Nurix Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nurix Therapeutics Inc (NAS:NRIX) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1700 Owens Street, Suite 205, San Francisco, CA, USA, 94158

Website

http://www.nurixtx.com

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Executives

Houte Hans Van	officer: Chief Financial Officer	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Christine Ring	officer: General Counsel	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Gwenn Hansen	officer: Chief Scientific Officer	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Stefani Wolff	officer: EVP and COO	C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Edward C Saltzman	director	C/O NURIX THERAPEUTICS, 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Paul M Silva	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Judith A Reinsdorf	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Pierre Beaurang	officer: Chief Business Officer	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Clay B Siegall	director	21823 30TH DR SE, BOTHELL WA 98021
Ponoi Capital, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Ii Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp	10 percent owner	1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129